Literature DB >> 25173187

Maternal morbidity in patients with morbidly adherent placenta treated with and without a standardized multidisciplinary approach.

Alireza A Shamshirsaz1, Karin A Fox2, Bahram Salmanian2, Concepcion R Diaz-Arrastia3, Wesley Lee2, B Wycke Baker4, Jerasimos Ballas2, Qian Chen2, Teelkien R Van Veen2, Pouya Javadian2, Haleh Sangi-Haghpeykar2, Nicholas Zacharias2, Stephen Welty5, Christopher I Cassady6, Amirhossein Moaddab2, Edwina J Popek7, Shiu-ki Rocky Hui7, Jun Teruya7, Venkata Bandi8, Michael Coburn9, Thomas Cunningham10, Stephanie R Martin2, Michael A Belfort2.   

Abstract

OBJECTIVE: The purpose of this study was to test the hypothesis that a standardized multidisciplinary treatment approach in patients with morbidly adherent placenta, which includes accreta, increta, and percreta, is associated with less maternal morbidity than when such an approach is not used (nonmultidisciplinary approach). STUDY
DESIGN: A retrospective cohort study was conducted with patients from 3 tertiary care hospitals from July 2000 to September 2013. Patients with histologically confirmed placenta accreta, increta, and percreta were included in this study. A formal program that used a standardized multidisciplinary management approach was introduced in 2011. Before 2011, patients were treated on a case-by-case basis by individual physicians without a specific protocol (nonmultidisciplinary group). Estimated blood loss, transfusion of packed red blood cells, intraoperative complications (eg, vascular, bladder, ureteral, and bowel injury), neonatal outcome, and maternal postoperative length of hospital stay were compared between the 2 groups.
RESULTS: Of 90 patients with placenta accreta, 57 women (63%) were in the multidisciplinary group, and 33 women (37%) were in the nonmultidisciplinary group. The multidisciplinary group had more cases with percreta (P = .008) but experienced less estimated blood loss (P = .025), with a trend to fewer blood transfusions (P = .06), and were less likely to be delivered emergently (P = .001) compared with the nonmultidisciplinary group. Despite an approach of indicated preterm delivery at 34-35 weeks of gestation, neonatal outcomes were similar between the 2 groups.
CONCLUSION: The institution of a standardized approach for patients with morbidly adherent placentation by a specific multidisciplinary team was associated with improved maternal outcomes, particularly in cases with more aggressive placental invasion (increta or percreta), compared with a historic nonmultidisciplinary approach. Our standardized approach was associated with fewer emergency deliveries.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  invasive placenta; maternal complication; placenta accreta; placenta increta; placenta percreta; standard treatment

Mesh:

Year:  2014        PMID: 25173187     DOI: 10.1016/j.ajog.2014.08.019

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  45 in total

1.  Assessment of the massive hemorrhage in placenta accreta spectrum with magnetic resonance imaging.

Authors:  Jie Zhang; Han Xu; Yinghui Xin; Chunhua Zhang; Zhiling Liu; Xue Han; Qingwei Liu; Yan Li; Zhaoqin Huang
Journal:  Exp Ther Med       Date:  2020-01-15       Impact factor: 2.447

2.  Prophylactic occlusion balloon placement in internal iliac arteries for the prevention of postpartum haemorrhage due to morbidly adherent placenta: short term outcomes.

Authors:  Salvatore Alessio Angileri; Leto Mailli; Claudio Raspanti; Anna Maria Ierardi; Gianpaolo Carrafiello; Anna-Maria Belli
Journal:  Radiol Med       Date:  2017-05-27       Impact factor: 3.469

3.  Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement.

Authors:  Manuel Muñoz; Jakob Stensballe; Anne-Sophie Ducloy-Bouthors; Marie-Pierre Bonnet; Edoardo De Robertis; Ino Fornet; François Goffinet; Stefan Hofer; Wolfgang Holzgreve; Susana Manrique; Jacky Nizard; François Christory; Charles-Marc Samama; Jean-François Hardy
Journal:  Blood Transfus       Date:  2019-02-06       Impact factor: 3.443

Review 4.  Management of patients with suspected placenta accreta spectrum.

Authors:  S C Reale; M K Farber
Journal:  BJA Educ       Date:  2021-12-21

5.  Population-based risk for peripartum hysterectomy during low- and moderate-risk delivery hospitalizations.

Authors:  Alexander M Friedman; Jason D Wright; Cande V Ananth; Zainab Siddiq; Mary E D'Alton; Brian T Bateman
Journal:  Am J Obstet Gynecol       Date:  2016-06-24       Impact factor: 8.661

6.  Risk of Peripartum Hysterectomy and Center Hysterectomy and Delivery Volume.

Authors:  Shravya Govindappagari; Jason D Wright; Cande V Ananth; Yongmei Huang; Mary E DʼAlton; Alexander M Friedman
Journal:  Obstet Gynecol       Date:  2016-12       Impact factor: 7.661

7.  Society of Abdominal Radiology (SAR) and European Society of Urogenital Radiology (ESUR) joint consensus statement for MR imaging of placenta accreta spectrum disorders.

Authors:  Priyanka Jha; Liina Pōder; Charis Bourgioti; Nishat Bharwani; Sara Lewis; Amita Kamath; Stephanie Nougaret; Philippe Soyer; Michael Weston; Rosa P Castillo; Aki Kido; Rosemarie Forstner; Gabriele Masselli
Journal:  Eur Radiol       Date:  2020-02-10       Impact factor: 5.315

8.  Are women antenatally diagnosed with abnormally invasive placenta receiving optimal management in England? An observational study of planned place of delivery.

Authors:  Will Sargent; Sally L Collins
Journal:  Acta Obstet Gynecol Scand       Date:  2018-11-15       Impact factor: 3.636

Review 9.  Pregnancy-Related Hysterectomy for Peripartum Hemorrhage: A Literature Narrative Review of the Diagnosis, Management, and Techniques.

Authors:  Dimitrios Tsolakidis; Dimitrios Zouzoulas; George Pados
Journal:  Biomed Res Int       Date:  2021-07-06       Impact factor: 3.411

Review 10.  A review and guide to creating patient specific 3D printed anatomical models from MRI for benign gynecologic surgery.

Authors:  Teresa E Flaxman; Carly M Cooke; Olivier X Miguel; Adnan M Sheikh; Sukhbir S Singh
Journal:  3D Print Med       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.